To date, life sciences’ efforts towards driving equitable healthcare have centered around access to care, early identification and prevention. Meanwhile, less attention has been given to the impact of the racial and ethnic homogeneity in trial populations. Clinical trial diversity…
Since the passage of the Inflation Reduction Act (IRA) in 2022, the pharmaceutical industry has significantly altered how they approach and plan for evidence generation activities to best support product launches and pricing and access negotiations. Leading life science companies…
The biopharmaceutical industry is known for its promise of life-changing innovations, but many companies continue to advance the wrong therapies into the clinic, resulting in underperformance and wasted resources. This white paper explores the concentration of activity on well-trodden ground,…
In 2023, the life sciences industry saw key therapeutic advances in sickle cell disease, obesity/weight management, and Duchenne muscular dystrophy, among others, and the continued approvals of therapies with cutting edge mechanisms, including the first CRISPR therapy. While 2022 was…
This report, the sixth in our Trinity Drug Index series, outlines key themes and emerging trends in the industry as we progress towards a new world of targeted and innovative products. We provide a comprehensive evaluation of the commercial performance…
Cell therapies are becoming increasingly incorporated as late-line standards of care across relapsed/refractory oncology indications, with an expanding ability to improve outcomes for a diverse set of tumors and patient subgroups. As the next frontier of personalized and precision medicine…
The pricing and market access (P&MA) landscape in China has been rapidly evolving as the country continuously attempts to balance rewarding innovation and sustainability of healthcare funding. China represents a unique and dynamic market archetype for manufacturers especially in terms…
Share estimates from demand studies in primary market research (PMR) are a critical input for any forecast—their accuracy is paramount for successful brand planning. Successful prediction is often elusive—from 2020 through 2022, only one in ten products had actual…
Trinity Life Sciences has been tracking and analyzing the challenges of commercialization and new product launches in the Biopharma industry for years (see our 2022 white paper, Empowering the Next-Generation Launch Model). One method we have leveraged to track the…
In the pharmaceutical industry, there has been ongoing discussion whether the Commercial Operations departments should become a globalized function. Over the past decade as companies have become more global in commercializing their products, organizations have been investigating the effectiveness of…